Drugs / ePGT121v1-LS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07390955 | Mar 2026 → Aug 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07655128 Comparator | Jan 2027 → Jul 2029 expected | HIV infectious disease | Hospital Universitario 12 de Octubre | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07655141 Comparator | Jan 2027 → Jul 2029 expected | HIV infectious disease | Hospital Universitario 12 de Octubre | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ePGT121v1-LS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07655141 ↗ |
| Modality | Monoclonal antibody | “lab-made antibody called ePGT121v1-LS” NCT07390955 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT07390955 ↗ |